Milestone Pharmaceuticals

MISTPhase 3

Montreal, CanadaFounded 2005milestonepharma.com

Milestone Pharmaceuticals is pioneering patient-administered therapies for episodic cardiovascular conditions, with its lead candidate etripamil representing a potential paradigm shift in the acute treatment of PSVT. The company has advanced etripamil through multiple Phase 3 clinical trials and is preparing for regulatory submissions. Their strategy focuses on leveraging a self-administered nasal spray formulation to empower patients and reduce healthcare system burdens associated with emergency care for acute arrhythmias.

Market Cap

$115.8M

Founded

2005

Employees

50-100

Focus

Biotech

MIST · Stock Price

USD 1.365.18 (-79.20%)

Historical price data

AI Company Overview

Technology Platform

Proprietary nasal spray delivery system for rapid self-administration of cardiovascular drugs, focusing on repurposed calcium channel blockers for episodic conditions.

Pipeline Snapshot

7 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Placebo + Etripamil	Atrial Fibrillation	Phase 3
Etripamil NS	Paroxysmal Supraventricular Tachycardia	Phase 3
Etripamil NS 70 mg + Placebo	Tachycardia, Supraventricular	Phase 3
Etripamil NS 70 mg	Paroxysmal Supraventricular Tachycardia	Phase 3
Etripamil NS	Paroxysmal Supraventricular Tachycardia	Phase 2

Funding History

Total raised: $180M

IPO$75MUndisclosedMay 10, 2019

Series C$53MNovo HoldingsMay 15, 2017

Series B$32MNovo HoldingsSep 15, 2014

Series A$20MForbionJun 15, 2011

Opportunities

Etripamil has first-in-class potential for PSVT with a large addressable patient population.

Expansion into AFib-RVR represents a significantly larger market opportunity.

The self-administered platform could be applied to other episodic cardiovascular conditions.

Risk Factors

Regulatory approval is not guaranteed and represents a binary event.

The company will need to raise additional capital.

Commercialization success depends on physician adoption of a new treatment paradigm and potential competition.

Competitive Landscape

No direct competitors with FDA-approved self-administered PSVT treatments. Competes against emergency department standard of care (IV adenosine, calcium channel blockers). InCarda Therapeutics is developing similar patient-administered approaches for atrial fibrillation.